FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
FTC says Optum, other prescription benefit managers inflate cancer drug prices 1,000%
Prescription benefit managers have been under growing scrutiny from state and federal regulators who have accused them of creating pharmacy deserts by steering consumers to their own pharmacies and driving independent pharmacists out of business.
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
Top three insurers reaped $7.3 billion through their drug middlemen’s markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ prescription price hikes of 1,000% or more.
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain
Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
Hosted on MSN10h
FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
pharmaphorum15h
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
Lawmaker may file bill to regulate PBMs: “They’re managing the dollar bill”
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
Star Tribune12d
Lawsuit in Minnesota deepens pharmacy benefit manager pushback against state regulations
The new lawsuit cites the fine as an example of how the Commerce Department has been “aggressively enforcing” the state’s PBM law. Following the consent order with CVS Caremark, the ...
Lawmaker may file bill to regulate PBMs: They’re managing the dollar
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Hosted on MSN10h
FTC Report Reveals PBM Practices Impacting Competition and Drug Costs
The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...